medparasitologyМедицинская паразитология и паразитарные болезниMedical Parasitology and Parasitic Diseases0025-83262713-1777Научно-образовательный паразитологический центр им. П.Г. Сергиева10.33092/0025-8326mp2025.1.42-52DNLLCUmedparasitology-15Research ArticleОБЗОРREVIEWОсновные направления и проблемы разработки вакцины против Toxoplasma gondiiThe main directions and problems in the development of a vaccine against Toxoplasma gondiiСтепановаЕ. В.StepanovaE. V.МаксимоваМ. С.MaksimovaM. S.ТурбабинаН. А.TurbabinaN. A.ДмитриевА. А.DmitrievA. A.ГромоваС. А.GromovaS. A.ЛатыповаМ. Ф.LatypovaM. F.МорозоваЛ. Ф.MorozovаL. F.МорозовЕ. Н.MorozovE. N.КондрашинА. В.KondrashinA. V.АникинаА. С.AnikinaA. S.ГончаровД. Б.GoncharovD. B.СергиевВ. П.SergievV. P.ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет); ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы» (НИИОЗММ ДЗМ)РоссияFSAE Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russian Federation; State Виdgetary Institution «Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Departament»Russian FederationФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияFSAE Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russian FederationRussian FederationГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы» (НИИОЗММ ДЗМ)РоссияState Виdgetary Institution «Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Departament»Russian FederationФГБУ «Национальный исследовательский центр эпидемиологии и микробиологии им. почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской ФедерацииРоссияThe Federal Government Budgetary Institution «National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation»Russian Federation202521042026014252Copyright © Научно-образовательный паразитологический центр им. П.Г. Сергиева, 20262026Научно-образовательный паразитологический центр им. П.Г. СергиеваНаучно-образовательный паразитологический центр им. П.Г. Сергиеваhttps://www.medparasitology.com/jour/about/submissions#copyrightNoticehttps://www.medparasitology.com/jour/article/view/15

Известно, что Toxoplasma gondii вызывает врожденную инфекцию у людей, животных и тяжелое заболевание у лиц с ослабленным иммунитетом. Поэтому разработка вакцин против паразита необходима. Несмотря на значительные успехи в разработке эффективных вакцин против токсоплазмоза, поиск новых стратегий вакцинации остается сложной задачей. За последние несколько лет различные экспериментальные подходы показали, что разработка вакцины против T. gondii возможна. В этом обзоре кратко излагаются достижения в разработке вакцин против T. gondii и основные препятствия на пути создания безопасной, эффективной и стандартизированной вакцины. Также обсуждаются успехи и неудачи в разработке и тестировании вакцин-кандидатов.

Toxoplasma gondii is known to cause congenital infection in humans, animals, and severe illness in immunocompromised individuals. Therefore, the development of vaccines against the parasite is necessary. Despite significant advances in the development of effective vaccines against toxoplasmosis, the search for new vaccination strategies remains challenging. Over the past few years, various experimental approaches have shown that the development of a vaccine against T. gondii is possible. This review summarizes the achievements in the development of T. gondii vaccines and the main obstacles to the creation of a safe, effective and long-lasting vaccine. Successes and failures in the development and testing of candidate vaccines are also discussed. 

Toxoplasma gondiiвакцинапаразитДНК-вакцинамРНК-вакциныэпитопные вакцинывакцины на основе углеводов.Toxoplasma gondiivaccineparasiteDNA vaccinemRNA vaccinesepitope vaccinescarbohydrate-based vaccinesReferencesСергиев В.П., Лобзин Ю.В., Козлов С.С. Паразитарные болезни человека (протозоозы и гельминтозы) // ООО «Издательство Фолиант», 2016: 640.Sergiev V.P., Lobzin Yu.V., Kozlov S.S. Human parasitic diseases (protozoan and helminthiasis) // Foliant Publishing House, 2016: 640. (in Russian)].Costa-Silva T.A., Borges M.M., Galhardo C.S., Pereira-Chioccola V.L. Immunization with excreted/secreted proteins in AS/n mice activating cellular and humoral response against Toxoplas-ma gondii infection // Acta Trop. 2012; 124:203–209. DOI: 10.1016/j.actatropica.2012.08.013.Costa-Silva T.A., Borges M.M., Galhardo C.S., Pereira-Chioccola V.L. Immunization with excreted/secreted proteins in AS/n mice activating cellular and humoral response against Toxoplas-ma gondii infection // Acta Trop. 2012; 124:203–209. DOI: 10.1016/j.actatropica.2012.08.013.Wang Y., Zhang D., Wang G., Yin H., Wang M. Immunization with excreted-secreted antigens reduces tissue cyst formation in pigs. Parasitol. Res. 2013; 112: 3835-3842. DOI: 10.1007/s00436-013-3571-4.Wang Y., Zhang D., Wang G., Yin H., Wang M. Immunization with excreted-secreted antigens reduces tissue cyst formation in pigs. Parasitol. Res. 2013; 112: 3835-3842. DOI: 10.1007/s00436-013-3571-4.Buxton D., Innes E.A. A commercial vaccine for ovine toxoplasmosis // Parasitology. 1995;110 Suppl: 11-6. DOI: 10.1017/s003118200000144xBuxton D., Innes E.A. A commercial vaccine for ovine toxoplasmosis // Parasitology. 1995;110 Suppl: 11-6. DOI: 10.1017/s003118200000144xDubey J.P. Toxoplasmosis in sheepthe last 20 years // Vet. Parasitol. 2009; 163: 1-14. DOI: 10.1016/j.vetpar.2009.02.026.Dubey J.P. Toxoplasmosis in sheepthe last 20 years // Vet. Parasitol. 2009; 163: 1-14. DOI: 10.1016/j.vetpar.2009.02.026.Chu K.B., Quan F.S. Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development // Vaccines (Basel). 2021; 9(5): 413. DOI: 10.3390/vaccines9050413.Chu K.B., Quan F.S. Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development // Vaccines (Basel). 2021; 9(5): 413. DOI: 10.3390/vaccines9050413.Гончаров Д.Б., Мезенцева М.В., Сургучёва И.М., Кобец Н.В., Игнатова Н.Г., Щербенко В.Э., Наровлянский А.Н. Продукция цитокинов при экспериментальном токсоплазмозе // Медицинская паразитология и паразитарные болезни. 2008; 1: 16-19.Goncharov D.B., Mezentseva M.V., Surgucheva I.M., Kobets N.V., Ignatova N.G., Shcherbenko V.E., Narovlyansky A.N. Cytokine production in experimental toxoplasmosis // Med Parasitol (Mosk). 2008; 1: 16-19. (in Russian)]Кобец Н.В., Зайцева Л.Г., Гончаров Д.Б. Губарева Е.В.., Мезенцева М.В., Киреева И.В., Сургучева И.М., Самойленко И.И. Иммунный ответ при токсоплазмозе после мукозальной иммунизации антигенами Toxoplasma gondii. // Медицинская паразитология и паразитарные болезни. 2010; 1: 10-14.Kobets N.V., Zaitseva L.G., Goncharov D.B., Gubareva E.V., Mezentseva M.V., Kireeva I.V., Surgucheva I.M., Samoylenko I.I. Immune response in toxoplasmosis after mucosal immunization with Toxoplasma gondii antigens // Med Parasitol (Mosk). 2010; 1: 10-14 (in Russian)]Кобец Н.В., Домонова Э.А., Гончаров Д.Б., Мезенцева М.В., Сильвейстрова О.Ю., Губарева Е.В., Шаповал И.М., Иевлева Е.С. Клеточные механизмы контроля диссеминации Toxoplasma gondii при парентеральном и пероральном заражении // Медицинская паразитология и паразитарные болезни. 2012; 4: 21-27.Kobets N.V., Domonova E.A., Goncharov D.B., Mezentseva M.V., Silveistrova O.Yu., Gubareva E.V., Shapoval I.M., Ievleva E.S. Cellular mechanisms of control of Toxoplasma gondii dissemination during parenteral and oral infection. // Med Parasitol (Mosk). 2012; 4: 21-27. (in Russian)]Xia D., Sanderson S.J., Jones A.R., Prieto J.H., Yates J.R., Bromley E., Tomley F.M., Lal K., Sinden R.E., Brunk B.P., Roos D.S., Wastling J.M. The proteome of Toxoplasma gondii: integration with the genome provides novel insights into gene expression and annotation // Genome Biol. 2008; 9(7): R116. DOI: 10.1186/gb-2008-9-7-r116.Xia D., Sanderson S.J., Jones A.R., Prieto J.H., Yates J.R., Bromley E., Tomley F.M., Lal K., Sinden R.E., Brunk B.P., Roos D.S., Wastling J.M. The proteome of Toxoplasma gondii: integration with the genome provides novel insights into gene expression and annotation // Genome Biol. 2008; 9(7): R116. DOI: 10.1186/gb-2008-9-7-r116.Ma G.Y., Zhang J.Z., Yin G.R., Zhang J.H., Meng X.L., Zhao F. Toxoplasma gondii: proteomic analysis of antigenicity of soluble tachyzoite antigen. Exp. Parasitol. 2009; 122: 41–46. DOI: 10.1016/j.exppara.2009.01.011.Ma G.Y., Zhang J.Z., Yin G.R., Zhang J.H., Meng X.L., Zhao F. Toxoplasma gondii: proteomic analysis of antigenicity of soluble tachyzoite antigen. Exp. Parasitol. 2009; 122: 41–46. DOI: 10.1016/j.exppara.2009.01.011.Weiss L.M., Ma Y.F., Takvorian P.M., Tanowitz H.B., Wittner M. Bradyzoite development in Toxoplasma gondii and the hsp70 stress response // Infect. Immun. 1998; 66: 3295-3302.Weiss L.M., Ma Y.F., Takvorian P.M., Tanowitz H.B., Wittner M. Bradyzoite development in Toxoplasma gondii and the hsp70 stress response // Infect. Immun. 1998; 66: 3295-3302.Silva N.M., Gazzinelli R.T., Silva D.A., Ferro E.A., Kasper L.H., Mineo J.R. Expression of Toxoplasma gondiispecific heat shock protein 70 during in vivo conversion of bradyzoites to tachyzoites // Infect. Immun. 1998; 66: 3959-3963.Silva N.M., Gazzinelli R.T., Silva D.A., Ferro E.A., Kasper L.H., Mineo J.R. Expression of Toxoplasma gondiispecific heat shock protein 70 during in vivo conversion of bradyzoites to tachyzoites // Infect. Immun. 1998; 66: 3959-3963.Czarnewski P., Araújo E.C.B., Oliveira M.C., Mineo T.W.P., Silva N.M. Recombinant TgHSP70 immunization protects against Toxo-plasma gondii brain cyst formation by enhancing inducible nitric oxide expression // Front. Cell Infect. Microbiol. 2017; 7: 142. DOI: 10.3389/fcimb.2017.00142.Czarnewski P., Araújo E.C.B., Oliveira M.C., Mineo T.W.P., Silva N.M. Recombinant TgHSP70 immunization protects against Toxo-plasma gondii brain cyst formation by enhancing inducible nitric oxide expression // Front. Cell Infect. Microbiol. 2017; 7: 142. DOI: 10.3389/fcimb.2017.00142.Onile O.S., Ojo G.J., Oyeyemi B.F., Agbowuro G.O., Fadahunsi A.I. Development of multiepitope subunit protein vaccines against Toxoplasma gondii using an immunoinformatics approach // NAR Genom Bioinform. 2020; 2: lqaa048. DOI: 10.1093/nargab/lqaa048.Onile O.S., Ojo G.J., Oyeyemi B.F., Agbowuro G.O., Fadahunsi A.I. Development of multiepitope subunit protein vaccines against Toxoplasma gondii using an immunoinformatics approach // NAR Genom Bioinform. 2020; 2: lqaa048. DOI: 10.1093/nargab/lqaa048.Zhang N.Z., Xu Y., Wang M., Chen J., Huang S.Y., Gao Q., Zhu X.Q. Vaccination with Toxoplasma gondii calciumdependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactidecoglycolide) microspheres induces longterm protective immunity in mice // BMC Infect Dis. 2016; 16: 168. DOI: 10.1186/s12879-016-1496-0.Zhang N.Z., Xu Y., Wang M., Chen J., Huang S.Y., Gao Q., Zhu X.Q. Vaccination with Toxoplasma gondii calciumdependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactidecoglycolide) microspheres induces longterm protective immunity in mice // BMC Infect Dis. 2016; 16: 168. DOI: 10.1186/s12879-016-1496-0.Foroutan M., Ghaffarifar F. Calcium-de-pendent protein kinases are potential targets for Toxoplasma gondii vaccine // Clin. Exp. Vaccin. Res. 2018; 7: 24-36. DOI: 10.7774/cevr.2018.7.1.24.Foroutan M., Ghaffarifar F. Calcium-de-pendent protein kinases are potential targets for Toxoplasma gondii vaccine // Clin. Exp. Vaccin. Res. 2018; 7: 24-36. DOI: 10.7774/cevr.2018.7.1.24.Majidiani H., Soltani S., Ghaffari A.D., Sabaghan M., Taghipour A., Foroutan M. Indepth computational analysis of calciumdependent protein kinase 3 of Toxoplasma gondii provides promising targets for vaccination // Clin. Exp. Vaccin. Res. 2020; 9: 146–158. DOI: 10.7774/cevr.2020.9.2.146.Majidiani H., Soltani S., Ghaffari A.D., Sabaghan M., Taghipour A., Foroutan M. Indepth computational analysis of calciumdependent protein kinase 3 of Toxoplasma gondii provides promising targets for vaccination // Clin. Exp. Vaccin. Res. 2020; 9: 146–158. DOI: 10.7774/cevr.2020.9.2.146.Dodangeh S., Fasihi-Ramandi M., Daryani A., Valadan R., Asgarian-Omran H., Hosseininejad Z., Nayeri Chegeni T., Pagheh A.S., Javidnia J., Sarvi S. Protective efficacy by a novel multiepitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB/c mice // Micro. Pathog. 2021; 153: 104764. DOI: 10.1016/j.micpath.2021.104764.Dodangeh S., Fasihi-Ramandi M., Daryani A., Valadan R., Asgarian-Omran H., Hosseininejad Z., Nayeri Chegeni T., Pagheh A.S., Javidnia J., Sarvi S. Protective efficacy by a novel multiepitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB/c mice // Micro. Pathog. 2021; 153: 104764. DOI: 10.1016/j.micpath.2021.104764.Warner R.C., Chapman R.C., Davis B.N., Davis P.H. Review of dna vaccine approaches against the parasite Toxoplasma gondii // J. Parasitol. 2021; 107: 882-903. DOI: 10.1645/20-157.Warner R.C., Chapman R.C., Davis B.N., Davis P.H. Review of dna vaccine approaches against the parasite Toxoplasma gondii // J. Parasitol. 2021; 107: 882-903. DOI: 10.1645/20-157.Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time // Nat. Rev. Genet. 2008; 9: 776-788. DOI: 10.1038/nrg2432.Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time // Nat. Rev. Genet. 2008; 9: 776-788. DOI: 10.1038/nrg2432.El Bissati K., Zhou Y., Paulillo S.M., Raman S.K., Karch C.P., Reed S., Estes A., Estes A., Lykins J., Burkhard P., McLeod R. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice // Sci. Rep. 2020; 10: 16984. DOI: 10.1038/s41598-020-73210-0.El Bissati K., Zhou Y., Paulillo S.M., Raman S.K., Karch C.P., Reed S., Estes A., Estes A., Lykins J., Burkhard P., McLeod R. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice // Sci. Rep. 2020; 10: 16984. DOI: 10.1038/s41598-020-73210-0.El Bissati K., Chentoufi A.A., Krishack P.A., Zhou Y., Woods S., Dubey J.P., Vang L., Lykins J., Broderick K.E., Mui E., Suzuki Y., Sa Q., Bi S., Cardona N., Verma S.K., Fraczek L., Reardon C.A., Sidney J., Alexander J., Sette A., Vedvick T., Fox C., Guderian J.A., Reed S., Roberts C.W., McLeod R. Adjuvanted multiepitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii // JCI Insight. 2016; 1: e85955. DOI: 10.1172/jci.insight.85955.El Bissati K., Chentoufi A.A., Krishack P.A., Zhou Y., Woods S., Dubey J.P., Vang L., Lykins J., Broderick K.E., Mui E., Suzuki Y., Sa Q., Bi S., Cardona N., Verma S.K., Fraczek L., Reardon C.A., Sidney J., Alexander J., Sette A., Vedvick T., Fox C., Guderian J.A., Reed S., Roberts C.W., McLeod R. Adjuvanted multiepitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii // JCI Insight. 2016; 1: e85955. DOI: 10.1172/jci.insight.85955.El Bissati K. et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014;32:3243-3248. DOI: 10.1016/j.vaccine.2014.03.092.El Bissati K. et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014;32:3243-3248. DOI: 10.1016/j.vaccine.2014.03.092.El Bissati K., Zhou Y., Dasgupta D., Cobb D., Dubey J.P., Burkhard P., Lanar D.E., McLeod R. Protein nanovaccine confers robust immunity against Toxoplasma // Vaccines. 2017; 2: 24. DOI: 10.1038/s41541-017-0024-6.El Bissati K., Zhou Y., Dasgupta D., Cobb D., Dubey J.P., Burkhard P., Lanar D.E., McLeod R. Protein nanovaccine confers robust immunity against Toxoplasma // Vaccines. 2017; 2: 24. DOI: 10.1038/s41541-017-0024-6.Roozbehani M., Falak R., Mohammadi M., Hemphill A., Razmjou E., Meamar A.R., Masoori L., Khoshmirsafa M., Moradi M., Gharavi M.J. Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection // Vaccine. 2018; 36: 6124-6132. DOI: 10.1016/j.vac-cine.2018.08.068.Roozbehani M., Falak R., Mohammadi M., Hemphill A., Razmjou E., Meamar A.R., Masoori L., Khoshmirsafa M., Moradi M., Gharavi M.J. Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection // Vaccine. 2018; 36: 6124-6132. DOI: 10.1016/j.vac-cine.2018.08.068.Luo F., Zheng L., Hu Y., Liu S., Wang Y., Xiong Z., Hu X., Tan F. Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate HydrolaseII (NTPase-II) Selfamplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP) // Front Microbiol. 2017; 8: 605. DOI: 10.3389/fmicb.2017.00605.Luo F., Zheng L., Hu Y., Liu S., Wang Y., Xiong Z., Hu X., Tan F. Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate HydrolaseII (NTPase-II) Selfamplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP) // Front Microbiol. 2017; 8: 605. DOI: 10.3389/fmicb.2017.00605.Pardi N., Hogan M.J., Weissman D. Recent advances in mRNA vaccine technology // Curr. Opin. Immunol. 2020; 65: 14-20. DOI: 10.1016/j.coi.2020.01.008.Pardi N., Hogan M.J., Weissman D. Recent advances in mRNA vaccine technology // Curr. Opin. Immunol. 2020; 65: 14-20. DOI: 10.1016/j.coi.2020.01.008.Maeda Y., Kinoshita T. Structural remodeling, trafficking and functions of glycosylphos-phatidylinositol-anchored proteins // Prog. Lipid Res. 2011; 50: 411-424. DOI: 10.1016/j.plip-res.2011.05.002.Maeda Y., Kinoshita T. Structural remodeling, trafficking and functions of glycosylphos-phatidylinositol-anchored proteins // Prog. Lipid Res. 2011; 50: 411-424. DOI: 10.1016/j.plip-res.2011.05.002.Debierre-Grockiego F., Campos M.A., Azzouz N., Schmidt J., Bieker U., Resende M.G., Mansur D.S., Weingart R., Schmidt R.R., Golenbock D.T., Gazzinelli R.T., Schwarz R.T. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii // J. Immunol. 2007; 179: 1129-1137. DOI: 10.4049/jimmunol.179.2.1129.Debierre-Grockiego F., Campos M.A., Azzouz N., Schmidt J., Bieker U., Resende M.G., Mansur D.S., Weingart R., Schmidt R.R., Golenbock D.T., Gazzinelli R.T., Schwarz R.T. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii // J. Immunol. 2007; 179: 1129-1137. DOI: 10.4049/jimmunol.179.2.1129.Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations // Nat. Rev. Drug Discov. 2010; 9: 308-324. DOI: 10.1038/nrd3012.Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations // Nat. Rev. Drug Discov. 2010; 9: 308-324. DOI: 10.1038/nrd3012.Li Y., Liu Y., Xiu F., Wang J., Cong H., He S., Shi Y., Wang X., Li X., Zhou H. Characterization of exosomes derived from Toxoplasma gondii and their functions in modulating immune responses // Int. J. Nanomed. 2018; 13: 467-477. DOI: 10.2147/IJN.S151110.Li Y., Liu Y., Xiu F., Wang J., Cong H., He S., Shi Y., Wang X., Li X., Zhou H. Characterization of exosomes derived from Toxoplasma gondii and their functions in modulating immune responses // Int. J. Nanomed. 2018; 13: 467-477. DOI: 10.2147/IJN.S151110.Aline F., Bout D., Amigorena S., Roingeard P., Dimier-Poisson I. Toxoplasma gondii antigen-pulsed-dendritic cellderived exosomes induce a protective immune response against T. gondii infection // Infect. Immun. 2004; 72: 4127-4137. DOI: 10.1128/IAI.72.7.4127-4137.2004.Aline F., Bout D., Amigorena S., Roingeard P., Dimier-Poisson I. Toxoplasma gondii antigen-pulsed-dendritic cellderived exosomes induce a protective immune response against T. gondii infection // Infect. Immun. 2004; 72: 4127-4137. DOI: 10.1128/IAI.72.7.4127-4137.2004.Santos P., Almeida F. Exosome-based vaccines: history, current state, and clinical trials. Front. Immunol // 2021; 12: 711565. DOI: 10.3389/fimmu.2021.711565.Santos P., Almeida F. Exosome-based vaccines: history, current state, and clinical trials. Front. Immunol // 2021; 12: 711565. DOI: 10.3389/fimmu.2021.711565.Yektaeian N., Malekpour A., Atapour A., Davoodi T., Hatam G. Genetic immunization against toxoplasmosis: a review article // Micro. Pathog. 2021; 155: 104888. DOI: 10.1016/j.mic-path.2021.104888.Yektaeian N., Malekpour A., Atapour A., Davoodi T., Hatam G. Genetic immunization against toxoplasmosis: a review article // Micro. Pathog. 2021; 155: 104888. DOI: 10.1016/j.mic-path.2021.104888.Attias M., Teixeira D.E., Benchimol M., Vommaro R.C., Crepaldi P.H., De Souza W. The lifecycle of Toxoplasma gondii reviewed using animations // Parasit. Vectors. 2020; 13: 588. DOI: 10.1186/s13071-020-04445-z.Attias M., Teixeira D.E., Benchimol M., Vommaro R.C., Crepaldi P.H., De Souza W. The lifecycle of Toxoplasma gondii reviewed using animations // Parasit. Vectors. 2020; 13: 588. DOI: 10.1186/s13071-020-04445-z.Cong H. et al. Human immunome, bio-informatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+ T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010;6:12. DOI: 10.1186/1745-7580-6-12.Cong H. et al. Human immunome, bio-informatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+ T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010;6:12. DOI: 10.1186/1745-7580-6-12.Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., Maewal A., McLeod R. Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination // mBio. 2015; 6: e02280. DOI: 10.1128/mBio.02280-14.Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., Maewal A., McLeod R. Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination // mBio. 2015; 6: e02280. DOI: 10.1128/mBio.02280-14.Dao A., Fortier B., Soete M., Plenat F., Dubremetz J.F. Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype // Int. J. Parasitol. 2001; 31: 63-65. DOI: 10.1016/S0020-7519(00)00151-X.Dao A., Fortier B., Soete M., Plenat F., Dubremetz J.F. Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype // Int. J. Parasitol. 2001; 31: 63-65. DOI: 10.1016/S0020-7519(00)00151-X.Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., Maewal A., McLeod R. Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional anti-bodies to multiple parasite strains // J. Infect. Dis. 2018; 218: 35-43. DOI: 10.1093/infdis/jiy170.Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., Maewal A., McLeod R. Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional anti-bodies to multiple parasite strains // J. Infect. Dis. 2018; 218: 35-43. DOI: 10.1093/infdis/jiy170.Tu V., Mayoral J., Sugi T., Tomita T., Han B., Ma Y.F., Weiss L.M. Enrichment and proteomic characterization of the cyst wall from in vitro Toxoplasma gondii cysts // mBio. 2019; 10(2): e00469-19. DOI: 10.1128/mBio.00469-19.Tu V., Mayoral J., Sugi T., Tomita T., Han B., Ma Y.F., Weiss L.M. Enrichment and proteomic characterization of the cyst wall from in vitro Toxoplasma gondii cysts // mBio. 2019; 10(2): e00469-19. DOI: 10.1128/mBio.00469-19.Waldman B.S. et al. Identification of a master regulator of differentiation in toxoplasma. Cell. 2020;180:359-372.e316. DOI: 10.1016/j.cell.2019.12.013.Waldman B.S. et al. Identification of a master regulator of differentiation in toxoplasma. Cell. 2020;180:359-372.e316. DOI: 10.1016/j.cell.2019.12.013.Inclan-Rico J.M., Siracusa M.C. First responders: innate immunity to helminths // Trends Parasitol. 2018; 34: 861–880. DOI: 10.1016/j.pt.2018.08.007.Inclan-Rico J.M., Siracusa M.C. First responders: innate immunity to helminths // Trends Parasitol. 2018; 34: 861–880. DOI: 10.1016/j.pt.2018.08.007.Buxton D. Toxoplasmosis: the first commercial vaccine // Parasitol. Today. 1993; 9: 335-337. DOI: 10.1016/0169-4758(93)90236-9.Buxton D. Toxoplasmosis: the first commercial vaccine // Parasitol. Today. 1993; 9: 335-337. DOI: 10.1016/0169-4758(93)90236-9.Sander V., Angel S.O., Clemente M. In Prospects of Plant-Based Vaccines in Veterinary Medicine (ed. MacDonald, J.). Springer International Publishing, 2018: 89–120.Sander V., Angel S.O., Clemente M. In Prospects of Plant-Based Vaccines in Veterinary Medicine (ed. MacDonald, J.). Springer International Publishing, 2018: 89–120.Sacks D.L., Peters N.C., Bethony J.M. In The Vaccine Book, 2nd edn. (eds. Bloom, B. R. & Lambert, P.-H.). Academic Press, 2016: Ch. 17, 331–360.Sacks D.L., Peters N.C., Bethony J.M. In The Vaccine Book, 2nd edn. (eds. Bloom, B. R. & Lambert, P.-H.). Academic Press, 2016: Ch. 17, 331–360.Sander V.A., Sánchez López E.F., Mendoza Morales L., Ramos Duarte V.A., Corigliano M.G., Clemente M. Use of veterinary vaccines for livestock as a strategy to control foodborne parasitic diseases // Front. Cell Infect. Microbiol. 2020; 10: 288. DOI: 10.3389/fcimb.2020.00288.Sander V.A., Sánchez López E.F., Mendoza Morales L., Ramos Duarte V.A., Corigliano M.G., Clemente M. Use of veterinary vaccines for livestock as a strategy to control foodborne parasitic diseases // Front. Cell Infect. Microbiol. 2020; 10: 288. DOI: 10.3389/fcimb.2020.00288.Freyre A., Choromanski L., Fishback J.L., Popiel I. Immunization of cats with tissue cysts, bradyzoites, and tachyzoites of the T-263 strain of Toxoplasma gondii // J. Parasitol. 1993; 79: 716-719. DOI: 10.2307/3283610.Freyre A., Choromanski L., Fishback J.L., Popiel I. Immunization of cats with tissue cysts, bradyzoites, and tachyzoites of the T-263 strain of Toxoplasma gondii // J. Parasitol. 1993; 79: 716-719. DOI: 10.2307/3283610.Ramakrishnan C., Maier S., Walker R.A., Rehrauer H., Joekel D.E., Winiger R.R., Basso W.U., Grigg M.E., Hehl A.B., Deplazes P., Smith N.C. An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats // Sci. Rep. 2019; 9: 1474. DOI: 10.1038/s41598-018-37671-8.Ramakrishnan C., Maier S., Walker R.A., Rehrauer H., Joekel D.E., Winiger R.R., Basso W.U., Grigg M.E., Hehl A.B., Deplazes P., Smith N.C. An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats // Sci. Rep. 2019; 9: 1474. DOI: 10.1038/s41598-018-37671-8.Sykes D., Rychtář J. A game-theoretic approach to valuating toxoplasmosis vaccination strategies // Theor. Popul. Biol. 2015; 105: 33-38. DOI: 10.1016/j.tpb.2015.08.003.Sykes D., Rychtář J. A game-theoretic approach to valuating toxoplasmosis vaccination strategies // Theor. Popul. Biol. 2015; 105: 33-38. DOI: 10.1016/j.tpb.2015.08.003.

The authors declare that there are no conflicts of interest present.